← All trials
NCT01221246
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2011
- Primary completion
- Jun 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Genervon Biopharmaceuticals, LLCLead sponsor
- Huntington Memorial HospitalOverall official - principal investigator
- Hoag Memorial Hospital PresbyterianOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- University of LouisvilleOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Sarasota Memorial HospitalOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- University of California, Los AngelesCollaborator
- Hoag Memorial Hospital PresbyterianCollaborator
- Columbia UniversityCollaborator
- University of LouisvilleCollaborator
- University of California, San FranciscoCollaborator
- Sarasota Memorial HospitalCollaborator
- University of Southern CaliforniaCollaborator
- University of Erlangen-NurembergCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.